Lisata Therapeutics (NASDAQ:LSTA) Lowered to Hold Rating by Zacks Research

Lisata Therapeutics (NASDAQ:LSTA) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

LSTA has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Lisata Therapeutics in a report on Thursday, August 21st. Brookline Capital Management raised their price objective on Lisata Therapeutics from $20.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, July 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Lisata Therapeutics has a consensus rating of “Hold” and a consensus target price of $23.50.

Lisata Therapeutics Price Performance

Shares of NASDAQ:LSTA opened at $2.10 on Monday. The company has a market capitalization of $18.39 million, a price-to-earnings ratio of -0.94 and a beta of 1.01. The firm’s 50 day simple moving average is $2.40 and its 200 day simple moving average is $2.50. Lisata Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $4.20.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.05. Equities research analysts expect that Lisata Therapeutics will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On Lisata Therapeutics

An institutional investor recently bought a new position in Lisata Therapeutics stock. Cerity Partners LLC acquired a new stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 12,183 shares of the company’s stock, valued at approximately $32,000. Cerity Partners LLC owned about 0.14% of Lisata Therapeutics as of its most recent SEC filing. 8.94% of the stock is owned by institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.